pyrroles has been researched along with Neoplasms, Cystic, Mucinous, and Serous in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bauerschlag, D; Baumann, KH; Canzler, U; Dewitz, T; du Bois, A; Hanker, LC; Hasenburg, A; Hillemanns, P; Hilpert, F; Kurzeder, C; Meier, W; Rau, J; Richter, B; Sehouli, J; Wagner, U; Wimberger, P; Wollschlaeger, K | 1 |
1 trial(s) available for pyrroles and Neoplasms, Cystic, Mucinous, and Serous
| Article | Year |
|---|---|
A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monother
Topics: Angiogenesis Inhibitors; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Indoles; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Platinum Compounds; Proportional Hazards Models; Pyrroles; Receptor Protein-Tyrosine Kinases; Sunitinib | 2012 |